Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity Extension Study of GPNV-001
NCT05982314Phase 2Completed
- Sponsor
- GPN Vaccines
- Start
- Jul 2023
- Primary completion
- Aug 2024
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 2 trial of gamma-pn3 in pneumococcal infection (6 arms), sponsored by GPN Vaccines. Primary endpoints: Serum IgG titre to Gamma-PN3 at 12 months and Serious adverse events at 12 months. Started Jul 2023; status: completed.
02
Drugs
gamma-pn3
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT05982314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05982314.